Collectively, our results support the existence of an ETV1‐EGFR‐STAT3 signaling axis in PCa cells with ETV1 overexpression, and the utility of repurposing Erlotinib in combination with a STAT3 inhibitor, may target with higher efficiency PCa cells with ETV1 overexpression. This evidence concerns the gene STAT3 and posterior cortical atrophy.